MF Researcher Database

Researcher Database

Advance

Kubota Yutaro

■FacultyMedical Oncology
■PositionSenior Lecturer
Last Updated :2025/04/01

Researcher

基本情報

Profile and Settings

  • 氏名

    Kubota Yutaro

Affiliation

  • Medical Oncology, Senior Lecturer

Location

  • University Hospital

Degree

  • Doctor of Medical Science, Showa University, Mar. 2009

Achievements

Published Papers

  • Efficacy of Recombinant Methioninase on Late-stage Patient Cancer in the Histoculture Drug Response Assay (HDRA) as a Potential Functional Biomarker of Sensitivity to Methionine-restriction Therapy in the Clinic., Kubota Yutaro;Sasaki Masato;Han Qinghong;Hozumi Chihiro;Tsunoda Takuya;Hoffman Robert M, Cancer diagnosis & prognosis, 4(3), May 2024, Peer-reviewed
  • Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody., Murayama Masakazu;Hosonuma Masahiro;Kuramasu Atsuo;Kobayashi Sei;Sasaki Akiko;Baba Yuta;Narikawa Yoichiro;Toyoda Hitoshi;Isobe Junya;Funayama Eiji;Tajima Kohei;Sasaki Aya;Maruyama Yuki;Yamazaki Yoshitaka;Shida Midori;Hamada Kazuyuki;Hirasawa Yuya;Tsurui Toshiaki;Ariizumi Hirotsugu;Ishiguro Tomoyuki;Suzuki Risako;Ohkuma Ryotaro;Kubota Yutaro;Horiike Atsushi;Sambe Takehiko;Tsuji Mayumi;Wada Satoshi;Kobayashi Shinichi;Shimane Toshikazu;Tsunoda Takuya;Kobayashi Hitome;Kiuchi Yuji;Yoshimura Kiyoshi, Scientific reports, 14(1), May 2024, Peer-reviewed
  • Precise Non-invasive Imaging Mouse Model of Pancreatic Cancer: Very Narrow Band-width Laser Fluorescence Excitation of Green Fluorescent Protein Provides Ultra-bright Tumor Images With no Skin Autofluorescence., Kubota Yutaro;Wang April;Chang Neil;Tarantino Samantha;Gallagher Sean;Aoki Yusuke;Masaki Noriyuki;Obara Koya;Morinaga Sei;Tsunoda Takuya;Hoffman Robert M, Cancer diagnosis & prognosis, 4(1), Jan. 2024, Peer-reviewed
  • Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reactions and survival of regorafenib in Japanese patients with colorectal cancer, Koutaro Ono; Remi Murase; Natsumi Matsumoto; Yutaro Kubota; Hiroo Ishida; Ken-ichi Fujita, Cancer Chemotherapy and Pharmacology, 2024, Peer-reviewed
  • [11C] Methionine-PET Imaging as a Cancer Biomarker for Methionine Addiction and Sensitivity to Methionine-restriction-based Combination Chemotherapy., Kubota Yutaro;Sato Toshihiko;Han Qinghong;Hozumi Chihiro;Morinaga Sei;Mizuta Kohei;Tsunoda Takuya;Hoffman Robert M, In vivo (Athens, Greece), 38(1), 2024, Peer-reviewed
  • Non-invasive Fluorescence Imaging of Breast Cancer Metastasis to the Brain in an Orthotopic Nude-mouse Model With Very-narrow-band-width Laser Excitation of Red Fluorescent Protein Resulting in an Ultra-bright Signal Without Skin Autofluorescence., Kubota Yutaro;Aoki Yusuke;Wang April;Chang Neil;Tarantino Samantha;Gallagher Sean;Tsunoda Takuya;Hoffman Robert M, In vivo (Athens, Greece), 38(1), 2024, Peer-reviewed
  • Methionine Dependence of Hair Maintenance in C57BL/6 Mice., Kubota Yutaro;Varshney Nundini;Kobayashi Keita;Tsunoda Takuya;Hoffman Robert M, In vivo (Athens, Greece), 38(3), 2024, Peer-reviewed
  • Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment., Hirasawa Yuya;Kubota Yutaro;Mura Emiko;Suzuki Risako;Tsurui Toshiaki;Iriguchi Nana;Ishiguro Tomoyuki;Ohkuma Ryotaro;Shimokawa Masahiro;Ariizumi Hirotsugu;Horiike Atsushi;Wada Satoshi;Ariyoshi Tomotake;Goto Satoru;Otsuka Koji;Murakami Masahiko;Kiuchi Yuji;Yoshimura Kiyoshi;Hoffman Robert M;Tsunoda Takuya, Anticancer research, 44(8):3397 - 3407, 2024, Peer-reviewed
  • Methionine restriction of glioma does not induce MGMT and greatly improves temozolomide efficacy in an orthotopic nude-mouse model: A potential curable approach to a clinically-incurable disease., Kubota Yutaro;Aoki Yusuke;Masaki Noriyuki;Obara Koya;Hamada Kazuyuki;Han Qinghong;Bouvet Michael;Tsunoda Takuya;Hoffman Robert M, Biochemical and biophysical research communications, 695, Dec. 2023, Peer-reviewed
  • Recombinant-methioninase-producing Escherichia coli Instilled in the Microbiome Inhibits Triple-negative Breast Cancer in an Orthotopic Cell-line Mouse Model., Kubota Yutaro;Han Qinghong;Morinaga Sei;Mizuta Kohei;Bouvet Michael;Tsunoda Takuya;Hoffman Robert M, Cancer diagnosis & prognosis, 3(6), Nov. 2023, Peer-reviewed
  • A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer, Yukitaka Shibata, Natsumi Matsumoto, Remi Murase, Yutaro Kubota, Hiroo Ishida, Ken Shimada, Ken-Ichi Fujita, Cancer Chemother Pharmacol, Aug. 2023, Peer-reviewed, DOI:doi.org/10.1007/s00280-023-04584-x
  • Old-age-induced obesity reversed by a methionine-deficient diet or oral administration of recombinant methioninase-producing Escherichia coli in C57BL/6 mice., Kubota Yutaro;Han Qinghong;Reynoso Jose;Aoki Yusuke;Masaki Noriyuki;Obara Koya;Hamada Kazuyuki;Bouvet Michael;Tsunoda Takuya;Hoffman Robert M, Aging, 15(11), Jun. 2023, Peer-reviewed
  • Synergy of Combining Methionine Restriction and Chemotherapy: The Disruptive Next Generation of Cancer Treatment., Kubota Yutaro;Han Qinghong;Aoki Yusuke;Masaki Noriyuki;Obara Koya;Hamada Kazuyuki;Hozumi Chihiro;Wong Andrew C W;Bouvet Michael;Tsunoda Takuya;Hoffman Robert M, Cancer diagnosis & prognosis, 3(3), May 2023, Peer-reviewed
  • Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor., Kazuyuki Hamada, Junya Isobe, Kouya Hattori, Masahiro Hosonuma, Yuta Baba, Masakazu Murayama, Yoichiro Narikawa, Hitoshi Toyoda, Eiji Funayama, Kohei Tajima, Midori Shida, Yuya Hirasawa, Toshiaki Tsurui, Hirotsugu Ariizumi, Tomoyuki Ishiguro, Risako Suzuki, Ryotaro Ohkuma, Yutaro Kubota, Takehiko Sambe, Mayumi Tsuji, Satoshi Wada, Yuji Kiuchi, Shinichi Kobayashi, Atsuo Kuramasu, Atsushi Horiike, Yun-Gi Kim, Takuya Tsunoda and Kiyoshi Yoshimura, Front Immunol., 14:1164724, May 2023, Peer-reviewed, DOI:10.3389/fimmu.2023.1164724
  • Superiority of [11C]methionine over [18F]deoxyglucose for PET Imaging of Multiple Cancer Types Due to the Methionine Addiction of Cancer., Kubota Yutaro;Sato Toshihiko;Hozumi Chihiro;Han Qinghong;Aoki Yusuke;Masaki Noriyuki;Obara Koya;Tsunoda Takuya;Hoffman Robert M, International journal of molecular sciences, 24(3), Jan. 2023, Peer-reviewed
  • Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study., Nio Yuta;Ishida Hiroo;Matsumoto Natsumi;Kusumoto Sojiro;Kubota Yutaro;Tsunoda Takuya;Sasaki Yasutsuna;Fujita Ken-Ichi, BMC pulmonary medicine, 22(1), Nov. 2022, Peer-reviewed
  • Case of Imatinib Susceptibility to CYP3A4-Mediated Drug-Drug Interactions in a Patient With Gastrointestinal Stromal Tumor., Fujimiya Tatsuhiro;Sugita Hideki;Kin Masaoki;Funakoshi Haruki;Kubota Yutaro;Tsunoda Takuya, American journal of therapeutics, 31(1), Jul. 2022, Peer-reviewed
  • Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction., Kubota Yutaro;Han Qinghong;Masaki Noriyuki;Hozumi Chihiro;Hamada Kazuyuki;Aoki Yusuke;Obara Koya;Tsunoda Takuya;Hoffman Robert M, Anticancer research, 42(12), 2022, Peer-reviewed
  • Long-term Stable Disease in a Rectal-cancer Patient Treated by Methionine Restriction With Oral Recombinant Methioninase and a Low-methionine Diet., Kubota Yutaro;Han Qinghong;Hamada Kazuyuki;Aoki Yusuke;Masaki Noriyuki;Obara Koya;Tsunoda Takuya;Hoffman Robert M, Anticancer research, 42(8), 2022, Peer-reviewed
  • Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease., Kubota Yutaro;Han Qinghong;Hozumi Chihiro;Masaki Noriyuki;Yamamoto Jun;Aoki Yusuke;Tsunoda Takuya;Hoffman Robert M, Anticancer research, 42(5), 2022, Peer-reviewed
  • Obesity Strongly Promotes Growth of Mouse MC38 Colon Cancer in an Orthotopic-syngeneic C57BL/6 Mouse Model., Hamada Kazuyuki;Kubota Yutaro;Aoki Yusuke;Sugisawa Norihiko;Yamamoto Jun;Tashiro Yoshihiko;Bouvet Michael;Tsunoda Takuya;Hoffman Robert M, In vivo (Athens, Greece), 36(4), 2022, Peer-reviewed
  • 食道がん・胃がん・大腸がんに対する薬物療法の最前線, 久保田　祐太郎, 昭和学士会雑誌, 81(3):139 - 153, Aug. 2021, Peer-reviewed
  • Characteristics of miRNA-SNPs in healthy Japanese subjects and non-small cell lung cancer, colorectal cancer, and soft tissue sarcoma patients., KATAYAMA Koki;NAKASHIMA Shimon;ISHIDA Hiroo;KUBOTA Yutaro;NAKANO Masataka;FUKAMI Tatsuki;SASAKI Yasutsuna;FUJITA Ken-ichi;NAKAJIMA Miki, Non-coding RNA Res, :e, Jun. 2021, Peer-reviewed
  • Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure., TSUBOYA Ayako;KUBOTA Yutaro;ISHIDA Hiroo;OHKUMA Ryotaro;ISHIGURO Tomoyuki;HIRASAWA Yuya;ARIIZUMI Hirotsugu;TSUNODA Takuya;SASAKI Yasutsuna;MATSUMOTO Natsumi;KONDO Yusuke;TOMODA Yukana;KUSUHARA Hiroyuki;FUJITA Ken-ichi, Cancer Chemother Pharmacol, :e, Jun. 2021, Peer-reviewed
  • The Prognostic Impact of Eosinophils and the Eosinophil-to-Lymphocyte Ratio on Survival Outcomes in Stage II Resectable Pancreatic Cancer., Ohkuma Ryotaro;Kubota Yutaro;Horiike Atsushi;Ishiguro Tomoyuki;Hirasawa Yuya;Ariizumi Hirotsugu;Watanabe Makoto;Onoue Rie;Ando Kiyohiro;Tsurutani Junji;Yoshimura Kiyoshi;Aoki Takeshi;Murakami Masahiko;Kobayashi Shinichi;Tsunoda Takuya;Wada Satoshi, Pancreas, 50(2), 2021, Peer-reviewed
  • Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer., Kubota Yutaro;Yoshimura Kiyoshi;Hamada Kazuyuki;Hirasawa Yuya;Shida Midori;Taniguchi Makoto;Matsui Hiroto;Ariizumi Hirotsugu;Ishiguro Tomoyuki;Suzuki Norihiro;Ohkuma Ryotaro;Sambe Takehiko;Ishida Hiroo;Horiike Atsushi;Wada Satoshi;Tsurutani Junji;Iwamoto Sanju;Uchida Naoki;Kiuchi Yuji;Kobayashi Shinichi;Tsunoda Takuya, In vivo (Athens, Greece), 35(3), 2021, Peer-reviewed
  • A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy., Hirasawa Yuya;Yoshimura Kiyoshi;Matsui Hiroto;Kubota Yutaro;Ishida Hiroo;Arai Jun;Sakaki Masashi;Oguro Nao;Shida Midori;Taniguchi Makoto;Hamada Kazuyuki;Ariizumi Hirotsugu;Ishiguro Tomoyuki;Ohkuma Ryotaro;Sambe Takehiko;Horiike Atsushi;Imamura Chiyo K;Shiozawa Eisuke;Wada Satoshi;Tsurutani Junji;Iwamoto Sanju;Uchida Naoki;Kiuchi Yuji;Tate Genshu;Kobayashi Shinichi;Tsunoda Takuya, Medicine, 100(23), 2021, Peer-reviewed
  • A Case of Cerebral Infarction During Treatment With Rivaroxaban for Venous Thromboembolism, KITAHARA Kanayuki ;MOMO Kenji;NIMURA Satomi;OKAZAKI Keinosuke;SUZUKI Norihiro;KUBOTA Yutaro;TSUNODA Takuya;WATANABE Daishi;MIZUMA Keita;ONO Kenjiro;SASAKI Tadanori, Am J Ther, 29(6):e673 - e676, Dec. 2020, Peer-reviewed
  • High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer., Ohkuma Ryotaro;Yada Erica;Ishikawa Shumpei;Komura Daisuke;Kubota Yutaro;Hamada Kazuyuki;Horiike Atsushi;Ishiguro Tomoyuki;Hirasawa Yuya;Ariizumi Hirotsugu;Shida Midori;Watanabe Makoto;Onoue Rie;Ando Kiyohiro;Tsurutani Junji;Yoshimura Kiyoshi;Sasada Tetsuro;Aoki Takeshi;Murakami Masahiko;Norose Tomoko;Ohike Nobuyuki;Takimoto Masafumi;Kobayashi Shinichi;Tsunoda Takuya;Wada Satoshi, International journal of oncology, 58(1), Nov. 2020, Peer-reviewed
  • Higher systemic exposure to unbound active metabolites of regorafenib is associated with short progression-free survival in colorectal cancer patients, KUBOTA Yutaro;FUJITA Ken-ichi;TAKAHASHI Takehiro;SUNAKAWA Yu;ISHIDA Hiroo;HAMADA Kazuyuki;ICHIKAWA Wataru;TSUNODA Takuya;SHIMADA Kazuhiro;MASUO Yusuke;KATO Yukio;SASAKI Yasutsuna, Clin Pharmacol Ther, 108(3):586 - 595, Sep. 2020, Peer-reviewed
  • Higher systemic exposure to unbound active metabolites of regorafenib is associated with short progression-free survival in colorectal cancer patients, KUBOTA Yutaro;FUJITA Ken-ichi;TAKAHASHI Takehiro;SUNAKAWA Yu;ISHIDA Hiroo;HAMADA Kazuyuki;ICHIKAWA Wataru;TSUNODA Takuya;SHIMADA Kazuhiro;MASUO Yusuke;KATO Yukio;SASAKI Yasutsuna, Clin Pharmacol Ther, 108(3):586 - 595, Sep. 2020, Peer-reviewed
  • A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors., Ando Kiyohiro;Hamada Kazuyuki;Shida Midori;Ohkuma Ryotaro;Kubota Yutaro;Horiike Atsushi;Matsui Hiroto;Ishiguro Tomoyuki;Hirasawa Yuya;Ariizumi Hirotsugu;Watanabe Makoto;Onoue Rie;Tsurutani Junji;Yoshimura Kiyoshi;Tsunoda Takuya;Kobayashi Shinichi;Wada Satoshi, Cancer immunology, immunotherapy : CII, 70(2), Aug. 2020, Peer-reviewed
  • Gastrointestinal Endoscopy for Patients with High Levels of Serum CEA and CA19-9, SUZUKI Norihiro;KATAGIRI Atsushi;NAKATANI Shinya;KIKUCHI Kazuo;GOCHO Toshihiko;YANAGISAWA Fumito;INOKI Kazuya;KONDA Kenichi;TOJO Masayuki;KUBOTA Yutaro;KONISHI Kazuo;YAMAMURA Fuyuhiko;YOSHIDA Hitoshi, Showa Univ J Med Sci, 32(2):115 - 123, Jul. 2020, Peer-reviewed
  • Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients, MATSUMOTO Natsumi;KUBOTA Yutaro;ISHIDA Hiroo;SEKIDO Masae;OHKUMA Ryotaro;ISHIGURO Tomoyuki;HIRASAWA Yuya;ARIIZUMI Hirotsugu;TSUNODA Takuya;IKUSUE Toshikazu;KOBAYASHI Kouji;HISAMATSU Atsushi;TOSHIMA Hirokazu;SHIMADA Ken;FUJITA Ken-ichi, Cancer Chemother Pharmacol, 85(6):1119 - 1128, Jun. 2020, Peer-reviewed
  • Association between macrocytosis and metachronous squamous cell carcinoma of the esophagus after endoscopic resection in men with early esophageal squamous cell carcinoma., KATADA C;YOKOYAMA T;YANO T;ODA I;SHIMIZU Y;DOYAMA H;KOIKE T;TAKIZAWA K;HIRAO M;OKADA H;YOSHII T;KUBOTA Yutaro;YAMANOUCHI T;TSUDA T;OMORI T;KOBAYASHI N;SUZUKI H;TANABE S;HORI K;NAKAYAMA N;KAWAKUBO H;KAKUSHIMA N;MATSUO Y;ISHIKAWA H;YOKOYAMA A;MUTO M, Esophagus, 17(2):149 - 158, Apr. 2020, Peer-reviewed
  • High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer., OHKUMA Ryotaro;YADA Erica;ISHIKAWA Shumpei;KOMURA Daisuke;ISHIZAKI Hidenobu;TAMADA Koji;KUBOTA Yutaro;HAMADA Kazuyuki;ISHIDA Hiroo;HIRASAWA Yuya;ARIIZUMI Hirotsugu;SATOH Etsuko;SHIDA Midori;WATANABE Makoto;ONOUE Rie;ANDO Kiyohiro;TSURUTANI Junji;YOSHIMURA Kiyoshi;YOKOBORI Takehiko;SASADA Tetsuro;AOKI Takeshi;MURAKAMI Masahiko;NOROSE Tomoko;OHIKE Nobuyuki;TAKIMOTO Masafumi;IZUMIZAKI Masahiko;KOBAYASHI Shinichi;TSUNODA Takuya;WADA Satoshi, PloS One, 15(1):e0226707, Jan. 2020, Peer-reviewed
  • High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer., OHKUMA Ryotaro;YADA Erica;ISHIKAWA Shumpei;KOMURA Daisuke;ISHIZAKI Hidenobu;TAMADA Koji;KUBOTA Yutaro;HAMADA Kazuyuki;ISHIDA Hiroo;HIRASAWA Yuya;ARIIZUMI Hirotsugu;SATOH Etsuko;SHIDA Midori;WATANABE Makoto;ONOUE Rie;ANDO Kiyohiro;TSURUTANI Junji;YOSHIMURA Kiyoshi;YOKOBORI Takehiko;SASADA Tetsuro;AOKI Takeshi;MURAKAMI Masahiko;NOROSE Tomoko;OHIKE Nobuyuki;TAKIMOTO Masafumi;IZUMIZAKI Masahiko;KOBAYASHI Shinichi;TSUNODA Takuya;WADA Satoshi, PloS One, 15(1):e0226707, Jan. 2020, Peer-reviewed
  • Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial., KATO K;CHO BC;TAKAHASHI M;OKADA M;LIN CY;CHIN K;KADOWAKI S;AHN MJ;HAMAMOTO Y;DOKI Y;YEN CC;KUBOTA Yutaro;KIM SB;HSU CH;HOLTVED E;XYNOS I;KODANI M;KITAGAWA Y, Lancet Oncol, 20(11):1506 - 1517, Nov. 2019, Peer-reviewed
  • Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors, ANDO Kiyohiro;HAMADA Kazuyuki;WATANABE Makoto;OHKUMA Ryotaro;SHIDA Midori;ONOUE Rie;KUBOTA Yutaro;MATSUI Hiroto;ISHIGURO Tomoyuki;HIRASAWA Yuya;ARIIZUMI Hirotsugu;TSURUTANI Junji;YOSHIMURA Kiyoshi;TSUNODA Takuya;KOBAYASHI Shinichi;WADA Satoshi, Anticancer Res, 39(9):5195 - 5201, Sep. 2019, Peer-reviewed
  • Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors, ANDO Kiyohiro;HAMADA Kazuyuki;WATANABE Makoto;OHKUMA Ryotaro;SHIDA Midori;ONOUE Rie;KUBOTA Yutaro;MATSUI Hiroto;ISHIGURO Tomoyuki;HIRASAWA Yuya;ARIIZUMI Hirotsugu;TSURUTANI Junji;YOSHIMURA Kiyoshi;TSUNODA Takuya;KOBAYASHI Shinichi;WADA Satoshi, Anticancer Res, 39(9):5195 - 5201, Sep. 2019, Peer-reviewed
  • Efficacy of Endoscopic Resection and Selective Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma., MINASHI K;NIHEI K;MIZUSAWA J;TAKIZAWA K;YANO T;EZOE Y;TSUCHIDA T;ONO H;IIZUKA T;HANAOKA N;ODA I;MORITA Y;TAJIKA M;FUJIWARA J;YAMAMOTO Y;KATADA C;HORI S;DOYAMA H;OYAMA T;NEBIKI H;AMAGAI K;KUBOTA Yutaro;NISHIMURA K;KOBAYASHI N;SUZUKI T;HIRASAWA K;TAKEUCHI T;FUKUDA H;MUTO M, Gastroenterology, 157(2):382 - 3.90E+05, Aug. 2019, Peer-reviewed
  • 腎癌および尿路上皮癌患者におけるバイオマーカー探索のための腸内細菌叢の研究, 下山　英明;直江　道夫;サト　プラサド　ネパール;平松　綾;松井　祐輝;鵜木　勉;中里　武彦;押野見　和彦;森田　順;前田　佳子;冨士　幸藏;小川　良雄;角田　卓也;吉村　清, 昭和学士会雑誌, 79(4):492 - 504, Aug. 2019, Peer-reviewed
  • Influx and efflux transporters contribute to the increased dermal exposure to active metabolite of regorafenib after repeated oral administration in mice, AL-SHAMMARI Aya Hasan;MASUO Yusuke;FUJITA Ken-ichi;YOSHIKAWA Yuka;NAKAMICHI Noritaka;KUBOTA Yutaro;SASAKI Yasutsuna;KATO Yukio, J Pharm Sci, 108(6):2173 - 2179, Jun. 2019, Peer-reviewed
  • Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil, SEKIDO Masae;FUJITA Ken-ichi;KUBOTA Yutaro;ISHIDA Hiroo;TAKAHASHI Takehiro;OHKUMA Ryotaro;TSUNODA Takuya;ISHIKAWA Fumihiro;SHIBANUMA Motoko;SASAKI Yasutsuna, Cancer Chemother Pharmacol, 83(6):1127 - 1135, Jun. 2019, Peer-reviewed
  • Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil, SEKIDO Masae;FUJITA Ken-ichi;KUBOTA Yutaro;ISHIDA Hiroo;TAKAHASHI Takehiro;OHKUMA Ryotaro;TSUNODA Takuya;ISHIKAWA Fumihiro;SHIBANUMA Motoko;SASAKI Yasutsuna, Cancer Chemother Pharmacol, 83(6):1127 - 1135, Jun. 2019, Peer-reviewed
  • Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal Failure, FUJITA Ken-ichi;MATSUMOTO Natsumi;ISHIDA Hiroo;KUBOTA Yutaro;IWAI Shinichi;SHIBANUMA Motoko;KATO Yukio, Curr Drug Metab, 20(5):361 - 376, Mar. 2019, Peer-reviewed
  • Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancer., TSUBOYA Ayako;FUJITA Ken-ichi;KUBOTA Yutaro;ISHIDA Hiroo;TAKI (TAKEMOTO) Iori;KAMEI Daisuke;IWAI Shinichi;SASAKI Yasutsuna, Int J Clin Oncol, 24(2):222 - 230, Feb. 2019, Peer-reviewed
  • Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan., SATOH Etsuko;SASAKI Yasutsuna;OHKUMA Ryotaro;TAKAHASHI Takehiro;KUBOTA Yutaro;ISHIDA Hiroo;HAMADA Kazuyuki;KIUCHI Yuji;TSUNODA Takuya, Cancer Sci, 109(12):3896 - 3901, Dec. 2018
  • Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan., SATOH Etsuko;SASAKI Yasutsuna;OHKUMA Ryotaro;TAKAHASHI Takehiro;KUBOTA Yutaro;ISHIDA Hiroo;HAMADA Kazuyuki;KIUCHI Yuji;TSUNODA Takuya, Cancer Sci, 109(12):3896 - 3901, Dec. 2018
  • A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11., SATAKE H;SUNAKAWA Y;MIYAMOTO Y;NAKAMURA M;NAKAYAMA H;SHIOZAWA M;MAKIYAMA A;KOBAYASHI K;KUBOTA Yutaro;MORI M;KOTAKA M;TAKAGANE A;GOTOH M;TAKEUCHI M;FUJII M;ICHIKAWA Wataru;SEKIKAWA Takashi, Oncotarget, 9(27):18811 - 18820, Apr. 2018, Peer-reviewed
  • Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, FUJITA Ken-ichi;MASUO Yusuke;YAMAZAKI Erina;SHIBUTANI Toshiki;KUBOTA Yutaro;NAKAMICHI Noritaka;SASAKI Yasutsuna;KATO Yukio, J Pharm Sci, 106(9):2632 - 2641, Sep. 2017, Peer-reviewed
  • Accuracy of the Differential Diagnosis of Colorectal Serrated Polyps Using a Conventional Endoscope: A Prospective Study, YANAGISAWA Fumito;KUBOTA Yutaro;KONISHI Kazuo;KATAGIRI Atsushi;MURAMOTO Takashi;KIHARA Toshihiro;YANO Yuichiro;TOJO Masayuki;SHINMURA Kensuke;KONDA Kenichi;TAGAWA Teppei;IIJIMA Kentaro;GOCHO Toshihiko;YAMAMURA Fuyuhiko;YAMOCHI Toshiko;TAKIMOTO Masafumi;YOSHIDA Hitoshi, Showa Univ J Med Sci, 29(3):253 - 261, Sep. 2017, Peer-reviewed
  • Toxicities of receptor tyrosine kinase inhibitors in cancer pharmacotherapy: management with clinical pharmacology, FUJITA Ken-ichi;ISHIDA Hiroo;KUBOTA Yutaro;SASAKI Yasutsuna, Curr Drug Metab, 18(3):186 - 198, Mar. 2017, Peer-reviewed
  • Immediate discontinuation of ablation during pulmonary vein isolation remarkably decreases the incidence of esophageal thermal lesions even when using steerable sheaths, WATANABE Norikazu;CHIBA Yuta;ONISHI Yoshimi;KAWASAKI Shiro;MUNETSUGU Yumi ;ONUMA Yoshimasa;ITOU Hiroyuki;ONUKI Tatsuya;MINOURA Yoshino;ADACHI Taro;KAWAMURA Mitsuharu;ASANO Taku;TANNO Kaoru;KUBOTA Yutaro;KONISHI Kazuo;KOBAYASHI Youichi, J Arrhythm, 33(1):23 - 27, Feb. 2017, Peer-reviewed
  • Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan., TAKATA Kosuke;FUJITA Ken-ichi;KUBOTA Yutaro;ISHIDA Hiroo;ICHIKAWA Wataru;SHIMADA Ken;SEKIKAWA Takashi;TAKI-TAKEMOTO Iori;KAMEI Daisuke;IWAI Shinichi;SASAKI Yasutsuna, J Pharm Health Care Sci, 2(30):1 - 9, Nov. 2016, Peer-reviewed
  • Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX, KAGA Yasuhiro;SUNAKAWA Yu;KUBOTA Yutaro;TAGAWA Teppei;YAMAMOTO Taikan;IKUSUE Toshikazu;UTO Yu;MIYASHITA Kouichirou;TOSHIMA Hirokazu;KOBAYASHI Kouji;HISAMATSU Atsushi;ICHIKAWA Wataru;SEKIKAWA Takashi;SHIMADA Ken;SASAKI Yasutsuna, Oncotarget, 7(41):67314 - 67320, Oct. 2016
  • Magnifying Colonoscopy Findings for Differential Diagnosis of Sessile Serrated Adenoma/Polyps and Hyperplastic Polyps , KIHARA Toshihiro;KUBOTA Yutaro;KONISHI Kazuo ;KATAGIRI Atsushi ;MURAMOTO Takashi ;YANO Yuichiro ;TOJO Masayuki;SHINMURA Kensuke;KONDA Kenichi ;TAGAWA,Teppei ;YANAGISAWA Fumito ;IIJIMA Kentaro ;GOCHO Toshihiko ;YAMAMURA Fuyuhiko;YAMOCHI Toshiko;TAKIMOTO Masafumi;YOSHIDA Hitoshi, Showa Univ J Med Sci, 28(2):147 - 154, Jun. 2016, Peer-reviewed, DOI:10.15369/sujms.28.147
  • Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer, FUJITA Ken-ichi;KUBOTA Yutaro;ISHIDA Hiroo;SASAKI Yasutsuna, World J Gastroenterol, 21(43):12234 - 12248, Nov. 2015, Peer-reviewed
  • Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?, SASAKI Yasutsuna;HAMADA Kazuyuki;KANETA Toshikado;TAKAHASHI Takehiro;KUBOTA Yutaro;ISHIDA Hiroo;ICHIKAWA Wataru, Cancer Sci, 106(8):1100, Aug. 2015, Peer-reviewed
  • Clinicopathological and Molecular Features of Laterally Spreading Tumors, KONDA Kenichi;KONISHI Kazuo;KATAGIRI Atsushi;NOZAWA Hisako;KUBOTA Yutaro;MURAMOTO Takashi;YANO Yuichiro;KIHARA Toshihiro;TOJO Masayuki;SHINMURA Kensuke;TAGAWA Teppei;YANAGISAWA Fumito;MAKINO Reiko;YOSHIDA Hitoshi, Showa Univ J Med Sci, 26(1):39 - 45, Mar. 2014, Peer-reviewed, DOI:10.15369/sujms.26.39
  • CpG Island Methylator Phenotype in Primary Gastric Carcinoma, TOJO Masayuki;KONISHI Kazuo;YANO Yuichiro;KATAGIRI Atsushi;NOZAWA Hisako;KUBOTA Yutaro;MURAMOTO Takashi;KONDA Kenichi;SHINMURA Kensuke;TAKIMOTO Masafumi;IMAWARI Michio;YOSHIDA Hitoshi, Showa Univ J Med Sci, 25(2):127 - 132, Jun. 2013, Peer-reviewed, DOI:doi.org/10.15369/sujms.25.127
  • 急性出血性直腸潰瘍における内視鏡的止血術についての検討, 野本　朋宏;竹内　義明;片桐　敦;新井　勝人;村元　喬;久保田　祐太郎;下問　祐;矢野　雄一郎;小林　祥也;岩田　朋之;大石　千歳;宮下　みゆき;魚住　祥二郎;大森　理沙;佐藤　悦基;井廻　道夫, Prog Dig Endosc, 78(2):61 - 66, 2, Jun. 2011, Peer-reviewed
  • Clinicopathological and molecular features of colorectal serrated neoplasias with different mucosal crypt patterns, YANO Yuichiro;KONISHI Kazuo;YAMOCHI Toshiko;KATAGIRI Atsushi;NOZAWA Hisako;SUZUKI Hiromu;TOYOTA Minoru;KUBOTA Yutaro;MURAMOTO Takashi;KOBAYASHI Yoshiya;TOJO Masayuki;KONDA Kenichi;MAKINO Reiko;YOSHIKAWA Nozomi;OTA Hidekazu;IMAWARI Michio, Am J Gastroenterol, 106(7):1351 - 1358, Jun. 2011

Presentations

  • A polymorphism in ABCC3 is associated with capecitabine-induced hand-foot syndrome and capecitabine pharmacokinetics, Kengo Omata, Natsumi Matsumoto, Remi Murase, Yutaro Kubota, Hiroo Ishida3 Ken Shimada, and Ken-ichi Fujita, 2025 the Japanese Society of Medical Oncology Annual Meeting, 06 Mar. 2025
  • Reduced systemic exposure to a capecitabine metabolite 5'-DFUR in ABCC4 polymorphism may be associated with increases in cAMP level and subsequent upregulation of thymidine phosphorylase, Natsumi Matsumoto, Ayano Oishi, Yutaro Kubota, Hiroo Ishida, Ken Shimada, Yusuke Masuo, Yukio Kato, Ken-ichi Fujita, ASCPT 2024 Annual Meeting, 28 Mar. 2024, American Society for Clinical Pharmacology & Therapeutics, Colorado Springs, United States
  • Reduced systemic exposure to a capecitabine metabolite 5'-DFUR in ABCC4 polymorphism may be associated with increases in cAMP level and subsequent upregulation of thymidine phosphorylase, Natsumi Matsumoto, Ayano Oishi, Yutaro Kubota, Hiroo Ishida, Ken Shimada, Yusuke Masuo, Yukio Kato, Ken-ichi Fujita, ASCPT 2024 Annual Meeting, 28 Mar. 2024, American Society for Clinical Pharmacology & Therapeutics, Colorado Springs, United States
  • Effect of VEGFA and CCL4L2 variants on hand-foot skin reaction and survival of regorafenib in Japanese patients with CRC, Koutaro Ono; Remi Murase; Natsumi Matsumoto; Yutaro Kubota; Hiroo Ishida; Ken-ichi Fujita, 2024 the Japanese Society Medical Oncology Annual Meeting, 22 Feb. 2024, Hirogi Iwata, Nagoya Congress Center
  • A polymorphisms in ABCA2 is associated with pharmacokinetics and toxicity of capecitabine in colorectal cancer patients, Yukitaka Shibata, Natsumi Matsumoto, Yutaro Kubota, Takuya Tsunoda, Hiroo Ishida, Ken Shimada, Ken-ichi Fujita, The 20th Japanese Society of Medical Oncology annual meeting, 16 Mar. 2023, fukuoka
  • Associations of polymorphisms in CCL4L1 with regorafenib-induced hand-foot skin reaction in colorectal cancer patients, Koutaro Ono, Remi Murase, Natsumi Matsumoto, Yutaro Kubota, Hiroo Ishida, Takuya Tsunoda, Yasutsuna Sasaki, Ken-ichi Fujita, 2023 the Japanese Society of Medical Oncology Annual Meeting. The 20th Anniversary Meeting, 16 Mar. 2023, Japanese Society of Medical Oncology, Fukuoka International Congress Center/ Marine Messe
  • Associations of HLA-C*01:02 and HLA-B*46:01 with regorafenib-induced erythema multiforme in Japanese patients with colorectal cancer., TAKESHIMA Kousuke;MATSUMOTO Natsumi;KUBOTA Yutaro;ISHIDA Hiroo;TSUNODA Takuya;SASAKI Yasutsuna;FUJITA Ken-ichi, 123rd American Society for Clinical Pharmacology and Therapeutics annual meeting (accepted)., 16 Mar. 2022, Web
  • Regorafenib-induced erythema multiforme is associated with HLA-C*01:02 and HLA-B*46:01 in Japanese cancer patients, 松本　奈都美;竹島　功高;久保田　祐太郎;石田　博雄;角田　卓也;佐々木　康綱;藤田　健一, 第19回日本臨床腫瘍学会学術集会(JSMO2022), 18 Feb. 2022, 京都＋Web開催
  • Pharmacokinetics and toxicity of gefitinib in elderly patients with EGFR mutated non-small cell lung cancer, 石田　博雄;仁尾　祐太;松本　奈都美;楠本　壮二郎;久保田　祐太郎;角田　卓也;佐々木　康綱;藤田　健一, 第19回日本臨床腫瘍学会学術集会(JSMO2022), 17 Feb. 2022, 京都＋Web開催
  • Pharmacokinetics and toxicity of gefitinib in elderly patients with EGFR mutated non-small cell lung cancer, 石田　博雄;仁尾　祐太;松本　奈都美;楠本　壮二郎;久保田　祐太郎;角田　卓也;佐々木　康綱;藤田　健一, 第19回日本臨床腫瘍学会学術集会(JSMO2022), 17 Feb. 2022, 京都＋Web開催
  • Assessment and risk control sheet facilitates management in cancer drug therapy, 本間　織重;渡邊　知映;福地本　晴美;柏崎　純子;園生　容子;我妻　志保;細沼　雅弘;久保田　祐太郎;倉増　敦朗;堀池　篤;石田　博雄;嶋田　顕;角田　卓也;梅田　恵;吉村　清, 第59回日本癌治療学会学術集会, 23 Oct. 2021, 横浜・LIVE配信・オンデマンド配信
  • 抗PD-1抗体で発症せず、抗PD-L1抗体投与後に血球貪食症候群様の免疫関連有害事象を発症した肺癌症例, 有泉　裕嗣;吉村　清;堀池　篤;平澤　優弥;石黒　智之;大熊　遼太朗;久保田　祐太郎;濵田　和幸;和田　聡;鶴谷　純司;角田　卓也, 第25回日本がん免疫学会総会, 03 Jul. 2021, 和歌山
  • SN-38の体内動態とOATP1B1の機能:重篤な腎機能障害のない患者において, 藤田　健一;久保田　祐太郎;石田　博雄;坪谷　綾子;角田　卓也;松本　奈都美;楠原　洋之;佐々木　康綱, 第18回日本臨床腫瘍学会学術集会 (JSMO2021), 18 Feb. 2021, オンデマンド配信
  • 抗悪性腫瘍薬イリノテカンの活性代謝物SN-38の体内動態とOATP1B1輸送活性との関連, 藤田　健一;久保田　祐太郎;石田　博雄;坪谷　綾子;角田　卓也;松本　奈都美;楠原　洋之;佐々木　康綱, 第41回日本臨床薬理学会学術総会, 05 Dec. 2020, 福岡およびWeb会場
  • ABCC4遺伝子多型のカペシタビンと代謝物の体内動態への影響, 松本　奈都美;久保田　祐太郎;角田　卓也;石田　博雄;嶋田　顕;増尾　友佑;加藤　将夫;藤田　健一, 第41回日本臨床薬理学会学術総会, 03 Dec. 2020, 福岡およびWeb会場
  • 体幹部定位放射線治療による肺合併症の実際, 楠本　壮二郎;岸野　康成;小林　玲;安藤　浩一;久保田　祐太郎;村上　幸三;堀池　篤;大森　亨;伊藤　芳紀;角田　卓也;相良　博典, 第61回日本肺癌学会学術集会, 14 Nov. 2020, 岡山およびライブ配信・オンデマンド配信
  • PS良好PD-L1高発現NSCLCに対するPembrolizumab療法とプラチナ製剤併用＋Pembrolizumab療法の有効性の検討, 岸野　康成;楠本　壮二郎;堀池　篤;有泉　裕嗣;久保田　祐太郎;安藤　浩一;田中　明彦;大森　亨;角田　卓也;相良　博典, 第61回日本肺癌学会学術集会, 12 Nov. 2020, 岡山およびライブ配信・オンデマンド配信
  • No effects of variants in carboxylesterase 1 gene on pharmacokinetics of capecitabine and its metabolites, 松本　奈都美;久保田　祐太郎;石田　博雄;関戸　匡恵;柴沼　質子;嶋田　顕;藤田　健一, 日本薬学会第140年会, 26 Mar. 2020, Web公開
  • Effect of a tyrosine kinase inhibitor regorafenib on the expression of xenobiotic transporters in the liver: Possible association with accumulation of its active metabolite., HASAN Aya Al-Shammari;MASUO Yusuke;FUJITA Ken-ichi;KUBOTA Yutaro;KATO Yukio, 日本薬物動態学会第34回年会, 11 Dec. 2019, つくば
  • 腸内細菌叢を介したがん免疫微小環境修飾によるがん患者の予後予測マーカーの同定に関する研究, 三邉　武彦;吉村　清;濵田　和幸;久保田　祐太郎;平澤　優弥;肥田　典子;龍　家圭;諸星　北人;角田　卓也;小林　真一;内田　直樹, 第40回日本臨床薬理学会学術総会, 06 Dec. 2019
  • ラベプラゾールの併用はカペシタビンと代謝物の体内動態に影響しない, 関戸　匡恵;藤田　健一;久保田　祐太郎;石川　文博;石田　博雄;柴沼　質子;佐々木　康綱, 第17回日本臨床腫瘍学会学術集会, 19 Jul. 2019, 京都
  • Expression of Olfactomedin-4 in pancreatic cancer and its clinical significance, OKUMA Ryotaro;KUBOTA Yutaro;HAMADA Kazuyuki;ISHIDA Hiroo;HIRASAWA Yuya;ARIIZUMI Hirotsugu;SATOH Etsuko;SHIDA Midori;WATANABE Makoto;TSURUTANI Junji;YOSHIMURA Kiyoshi;AOKI Takeshi;MURAKAMI Masahiko;NOROSE Tomoko;OHIKE Nobuyuki;TAKIMOTO Masafumi;TSUNODA Takuya;WADA Satoshi, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 18 Jul. 2019, 京都
  • AUC of unbound form of regorafenib active metabolites M2 and M5 are associated with hand-foot syndrome, and ABCG2 polymorphism in Japanese patients with colorectal cancer, FUJITA Ken-ichi;KUBOTA Yutaro;MASUO Yusuke;ISHIDA Hiroo;KATO Yukio;SASAKI Yasutsuna, 120th American Society for Clinical Pharmacology and Therapeutics annual meeting, 14 Mar. 2019, Washington DC
  • Accumulation of active metabolite of anticancer agent regorafenib involves nonlinear hepatic distribution after repeated dose, AL-SHAMMARI Aya Hasan;MASUO Yusuke;FUJITA Ken-ichi;KUBOTA Yutaro;SASAKI Yasutsuna;KATO Yukio, 2018 International Meeting on 22nd MDO and 33rd JSSX, 04 Oct. 2018, Kanazawa
  • Involvement of ABC drug transporters in disposition of tyrosine kinase inhibitor regorafenib and its active metabolites after repeated oral dose, HASAN Aya;MASUO Yusuke;FUJITA Ken-ichi;YAMAZAKI Erina;KUBOTA Yutaro;NAKAMICHI Noritaka;SASAKI Yasutsuna;KATO Yukio, 日本薬物動態学会第32回年会, 29 Nov. 2017, 東京
  • Keratinocyteにおける膜輸送体の発現とレゴラフェニブ分布に及ぼす影響, 島田　和弘;増尾　友佑;藤田　健一;山﨑　絵里名;久保田　祐太郎;中道　範隆;佐々木　康綱;加藤　将夫, 日本薬学会北陸支部第129回例会, 26 Nov. 2017, 金沢
  • Involvement of ABC transporters in tissue distribution and disposition of active metabolites of regorafenib, FUJITA Ken-ichi;YAMAZAKI Erina;MASUO Yusuke;NAKAMICHI Noritaka;KUBOTA Yutaro;SASAKI Yasutsuna;KATO Yukio, 第15回日本臨床腫瘍学会学術集会, 27 Jul. 2017, 神戸
  • 胸腔鏡下食道亜全摘術を施行した食道悪性黒色腫の1例, 藤井　智徳;村上　雅彦;加藤　礼;山下　剛史;五藤　哲;久保田　祐太郎;佐々木　康綱, 第71回日本食道学会学術集会, 16 Jun. 2017, 軽井沢町
  • Roles of BCRP and P-gp in disposition of regorafenib and active metabolites M-2 and M-5, FUJITA Ken-ichi;MASUO Yusuke;KUBOTA Yutaro;SASAKI Yasutsuna;KATO Yukio, 第75回日本癌学会学術総会, 08 Oct. 2016, 横浜
  • Concurrent radiotherapy with gemcitabine in patients with locally advanced pancreatic cancer: a retrospective analysis, NOMOTO Tomohiro;KITAMURA Katsuya;HONMA Tadashi;ISHII Yu;YAMAMIYA Akira;KUBOTA Yutaro;SHINJO Hidenori;KAGAMI Yoshikazu;YOSHIDA Hitoshi, The 20th meeting of the International Association of Pancreatology・The 47th annual meeting of the Japan Pancreas Society・The 6th meeting of the Asian-Oceanic Pancreatic Association, 06 Aug. 2016, Sendai
  • Comparison of cancer drug approval by PMDA in the US, SATOH Etsuko;ISHIDA Hiroo;TAKAHASHI Takehiro;KUBOTA Yutaro;KUSUMOTO Sojiro;KISHINO Yasunari;TOJO Masayuki;HAMADA Kazuyuki;SASAKI Yasutsuna, 第14回日本臨床腫瘍学会学術集会, 29 Jul. 2016, 神戸
  • Comprehensive analysis of miRNA-variants in Japanese healthy subjects, non-small cell lung carcinoma and colorectal cancer patients, KATAYAMA Koki;GOTOH Saki;FUKAMI Tatsuya;ISHIDA Hiroo;KUBOTA Yutaro;KUSUMOTO Sojiro;FUJITA Ken-ichi;SASAKI Yasutsuna;NAKAJIMA Miki, 日本薬物動態学会第30回年会, 12 Nov. 2015, 東京

Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.